Clinical vaccine development and biomanufacturing

M1

Course Goals 

1. To give an overview of . vaccine biomanufacturing including considerations for taking pre-clinical vaccine candidates into GMP manufacture, the principles of GMP (good manufacturing practice), and an overview of small to large scale manufacture.

2. To provide an overview of vaccine clinical development including examples from experimental and licensed vaccines; to impart the importance of clinical trial design, immunomonitoring, statistical considerations and ethical considerations.

Timeline 

Application Deadline:
15 July 2020

Course Dates:
21-24 September 2021 (4 days)

Organiser

University of Oxford (UOXF)/Oxford, UK

​
Participant Nr.: 12

Contact

Wendy Crocker wendy.crocker@ndm.ox.ac.uk

Course content

A list of the course contents is given on the website, link below. It includes a visit to a small-scale biomanufacturing facility. For more in-depth information on course content and structure check https://www.conted.ox.ac.uk/courses/clinical-vaccine-development-and-biomanufacturing?code=C900-5

Learning Outcomes

A. To gain an understanding of the vaccine development process, including GMP manufacture and testing vaccine safety and efficacy in clinical trials.

B. To be able to apply the understanding to vaccines being designed, manufactured and developed by the participant

Who should apply

Anyone working in vaccinology, or interested in learning about the vaccine clinical development process, including those from academia, industry, or regulatory bodies.

Minimal requirements

None, but ideally a background in biological science and/or first degree in related subject.

Accommodation

Accommodation will be provided. Travel Costs are not included.

Comments

NA

How to apply>>​

​

Kindly note that not all courses are open for application submission, check open calls to know which for which courses you can apply for at the moment.


Be the first to know about the upcoming application calls, follow European Vaccine Initiative on Twitter and LinkedIn or subscribe to TRANSVAC Newsletter